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Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by dopamin-
ergic neuron-specific degeneration in the substantia nigra. A number of gene mutations and dele-
tions have been reported to play a role in the pathogenesis of familial PD. Moreover, a number of
pathological and pharmacological studies on sporadic PD and dopaminergic neurotoxin-induced
parkinsonism have hypothesized that mitochondrial dysfunction, inflammation, oxidative stress,
and dysfunction of the ubiquitin-proteasome system all play important roles in the pathogene-
sis and progress of PD. However, these hypotheses do not yet fully explain the mechanisms of
dopaminergic neuron-specific cell loss in PD. Recently, the neurotoxicity of dopamine quinone
formation by auto-oxidation of dopamine has been shown to cause specific cell death of dopamin-
ergic neurons in the pathogenesis of sporadic PD and dopaminergic neurotoxin-induced parkin-
sonism. Furthermore, this quinone formation is closely linked to other representative hypotheses
in the pathogenesis of PD. In this article, we mainly review recent studies on the neurotoxicity of
quinone formation as a dopaminergic neuron-specific oxidative stress and its role in the etiology of
PD, in addition to several neuroprotective approaches against dopamine quinone-induced toxicity.
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Parkinson’s disease(PD)is a progressive neurodegenerative disease characterized by dopaminergic neuron-speciﬁc degeneration in the substantia nigra. A number of gene mutations and deletions have been reported to play a role in the pathogenesis of familial PD. Moreover, a number of pathological and pharmacological studies on sporadic PD and dopaminergic neurotoxin-induced parkinsonism have hypothesized that mitochondrial dysfunction, inﬂammation, oxidative stress,
and dysfunction of the ubiquitin-proteasome system all play important roles in the pathogenesis and progress of PD. However, these hypotheses do not yet fully explain the mechanisms of dopaminer-
gic neuron-speciﬁc cell loss in PD. Recently, the neurotoxicity of dopamine quinone formation by auto-oxidation of dopamine has been shown to cause speciﬁc cell death of dopaminergic neurons in the pathogenesis of sporadic PD and dopaminergic neurotoxin-induced parkinsonism. Furthermore,
this quinone formation is closely linked to other representative hypotheses in the pathogenesis of PD. In this article, we mainly review recent studies on the neurotoxicity of quinone formation as a dopaminergic neuron-speciﬁc oxidative stress and its role in the etiology of PD, in addition to several neuroprotective approaches against dopamine quinone-induced toxicity.
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P arkinson’s disease(PD)is a progressive neuro-degenerative disease characterized by degenera-
tion of dopamine (DA)-containing neurons in the sub-
stantia nigra and by the presence of Lewy bodies. A number of eﬃcient therapeutic drugs, including L-
DOPA, dopamine agonists, and inhibitors of dopamine-
metabolizing enzymes, have been used for the clinical treatment of patients with PD. It has been shown that several genes are mutated or deleted in familial PD, but the etiology of sporadic PD, which accounts for the
 
majority of PD cases, is still obscure. A number of important results have been accumulated from pathological and pharmacological studies on PD and from animal or in vitro studies using dopaminergic neurotoxins which cause parkinsonism in animals. These studies have shown that
(1) mitochondrial dysfunction, (2) inﬂammation, (3)
oxidative stress, and (4) impairment of the ubiquitin-
proteasome system play important roles in the path-
ogenesis and progress of sporadic and familial PD.
However, the mechanisms of dopaminergic neuron-
speciﬁc cell loss in PD have not been fully clariﬁed. More recently, an additional factor, (5)DA quinone formation,
has been investigated with respect to not only L-DOPA-
induced neurotoxicity but also the pathogenesis of PD and
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dopaminergic neurotoxin-induced parkinsonism［1-3］.
This article focuses on the neurotoxicity of quinone formation as a dopaminergic neuron-speciﬁc oxidative stress and its role in the etiology of PD by reviewing studies on patients with sporadic PD and studies employ-
ing models of sporadic PD induced by dopaminergic neurotoxins. In addition, neuroprotective approaches against DA quinone toxicity are also addressed.
Dopaminergic Neurotoxin-induced Parkinsonism―Involvement of Mitochondrial Dysfunction, Inﬂammation,
Oxidative Stress, and Proteolytic Stress―
Following the initial reports that a dopaminergic neurotoxin, 1-methyl-4-phe n y l-1, 2, 3, 6-
tetrahydropyridine(MPTP), caused irreversible parkin-
sonism with progressive depletion of DA neurons in the substantia nigra［4, 5］, the neurotoxic mechanism of MPTP has been widely investigated and has been used as a representative dopaminergic neurotoxin in animal models of PD. MPTP which across the blood-brain barrier is converted to 1-methyl-4-phenylpyridinium (MPP?) by monoamine oxidase-B in the glial cells. MPP?can be selectively up-taken through DA transporters at the nerve endings of nigrostriatal DA neurons, and then inhibit mitochondrial complex I to cause cell death of DA neurons［6, 7］. Furthermore, MPTP-induced parkin-
sonism is responsive to L-DOPA. It has been reported that  an other dopaminergic neurotoxin, 6-
hydroxydopamine(6-OHDA), which has been commonly used to make in vivo and in vitro models of PD, also induces mitochondrial impairment by inhibiting mitochon-
drial complexes I and IV［8-10］and reducing cyto-
chrome c［11］, although there have been reported that 6-OHDA does not in fact impair mitochondrial function
［12, 13］. Therefore, these ﬁndings imply the hypothesis of mitochondrial dysfunction:inhibition of mitochondrial respiratory enzymes by certain environmental neurotoxin which up-taken into DA neurons may cause selective neuronal loss of DA neurons in the substantia nigra.
Betarbet et al.revealed that chronic and systemic infusion of the lipophilic pesticide, rotenone, which is an inhibitor of mitochondrial complex I, causes parkinsonism with hypokinesia and rigidity in rats with highly selective nigrostriatal dopaminergic degeneration and ﬁbrillar cyto-
plasmic inclusions containing ubiquitin andα-synuclein.
These results indicate that chronic exposure to a common
 
pesticide can reproduce the anatomical, neurochemical,
behavioral and neuropathological features of PD［14］.
The dopaminergic neurotoxicity of rotenone strongly supports the possible involvement of mitochondrial dysfunction in the pathogenesis of PD, although it is unclear how rotenone, which inhibits complex I systemically, produces selective degeneration of DA neurons.
Intracerebral injection of bacterial endotoxin lipopolysaccharide(LPS)has been shown to induce the expression of inﬂammatory cytokines and their related molecules, i.e., interleukin(IL)-1β, IL-6, IL-12, p35,
tissue necrosis factor(TNF)-α, and inducible nitric oxide synthase(iNOS)［15］. Furthermore, intranigral injec-
tion of inﬂammogen LPS has been shown to induce degeneration of nigral DA neurons with accumulation of microglia in rats［16, 17］. These reports showed that the microglial activation and inﬂammatory reaction in-
duced by chronic exposure to the inﬂammogen were capable of inducing selective degeneration of nigral dopaminergic neurons. In animal models treated with MPTP, astroglial and microglial reactions and lymphocytic inﬁltration were found around impaired neu-
rons in the substantia nigra, suggesting that an immune mechanism contributed to the MPTP-induced neuronal damage［18］. As for the neurotoxicity of rotenone, this may be at least partly due to the inﬂammatory reaction occurring in conjunction with activation of microglia.
Marked microglial activation has been observed in the striatum and substantia nigra of rotenone-treated animals,
and was prominent before anatomical evidence of dopaminergic lesions［19］. Rotenone stimulated the release of superoxide from microglia, and this release was attenuated by inhibitors of NADPH oxidase. The rotenone-induced neurotoxicity was also reduced by the inhibition of NADPH oxidase or scavenging of superox-
ide［20］. In primary mesencephalic neuron-glia cultures,
dopaminergic neurons from NADPH oxidase-null mice were more resistant to rotenone neurotoxicity［21］.
Furthermore, nontoxic or minimally toxic concentrations of the pesticide rotenone(0.5 nM)and LPS (0.5 ng/ml)
synergistically induced dopaminergic neurodegeneration in primary mesencephalic mixed cultures. All these ﬁndings indicate that rotenone-induced dopaminergic neurotoxicity may be based not only on mitochondrial dysfunction but also on inﬂammatory reaction and free radical generation through microglial activation, and that inhibition of inﬂammation might become a promising therapeutic inter-
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vention for PD［22］. In other words, further studies on the selectively toxic mechanisms of rotenone may eluci-
date the multifactorial etiology of PD. In fact, the dopaminergic neurotoxicity induced by MPTP, MPP?
and 6-OHDA was inhibited and ameliorated by treatment with aspirin, salicylate and meloxicam,which are nonster-
oidal anti-inﬂammatory drugs (NSAIDs) inhibiting cyclooxygenase (COX)［23-26］, and minocycline,
which is a tetracycline derivative that inhibits microglial activation independently of its antimicrobial properties
［27-29］.
As mentioned above, oxidative stress with generation of reactive oxygen species (ROS)or reactive nitrogen species (RNS)is known to play important roles in the pathogenesis and progress of PD as a common degenera-
tive process. Superoxide generated is leaked from mito-
chondria in the case of its dysfunction, especially when the activity of mitochondrial respiratory enzymes reduced by neurotoxins, MPTP, 6-OHDA and rotenone. Non-
enzymatic and spontaneous auto-oxidation of DA produce superoxide and reactive quinones［30, 31］. In the inﬂammatory process, superoxide is also generated in activated microglia through NADPH oxidase or xanthine oxidase. The superoxide generated is converted to hydro-
gen peroxide by superoxide dismutase(SOD), and super-
oxide also reacts with nitric oxide to consequently gener-
ate peroxynitrite, which is a highly RNS that leads protein nitration. Hydrogen peroxide is up-taken into neurons and normally reduced by antioxidants such as glutathione (GSH), glutathione peroxidase (GPx) or catalase. Where transition metals, especially iron, are abundant, however, hydrogen peroxide reacts with metals to form the most cytotoxic ROS, hydroxyl radi-
cals. The generation of ROS［32-34］and compensatory elevation of antioxidative enzymes, SOD, GPx and catalase［35］were reported in the basal ganglia of MPTP-treated animals or MPP?-treated cultured cells.
Furthermore, dopaminergic neurotoxicity induced by MPTP administration was inhibited in Cu/Zn-SOD transgenic mice［36］. Neurotoxic 6-OHDA is up-taken into striatal nerve endings of dopaminergic neurons through DA transporters, and the toxin produces ROS such as superoxide, hydrogen peroxide and hydroxyl radicals when it is converted to reactive quinones by auto-oxidation［37, 38］. We have previously reported that the intracerebroventricular injection of 6-OHDA produced marked increases in Cu/Zn-SOD activity and lipid peroxides in the striatum［39］and that 6-OHDA-
induced reduction of nigral DA neurons was prevented in Cu/Zn-SOD transgenic mice［40］. Rotenone also pro-
duces the release of superoxide from microglia through activation of NADPH oxidase［20, 21］.
The generated hydrogen peroxide activates NF-κB transcription factor, which is related to inﬂammation［41,
42］, and consequently promotes transcription of iNOS,
COX, inﬂammatory cytokines (IL-1β, IL-6, TNF-α)
and apoptosis-promoting molecules (p53, Bcl-Xs, Bax)
［43］. The inﬂammatory cytokines activate iNOS expres-
sion directly or indirectly through activation of NF-κB and thereby start a vicious cycle. It is known that superoxide and hydrogen peroxide can open mitochondrial permeability transition pores directly or indirectly through the activation of NF-κB and Bax protein［44］to pro-
mote the release of cytochrome c and consequent apoptotic cell death. Nitric oxide also inhibits mitochon-
drial respiratory enzymes to leak superoxide［45］. Thus,
mitochondrial dysfunction, inﬂammation, and oxidative stress by generated ROS or RNS seem to be linked to each other in establishing the pathogenesis of parkin-
sonism by dopaminergic neurotoxins in nigrostriatal DA neurons and surrounding glial cells (Fig. 1).
Other possible hypothesis, which is proteolytic stress,
has been recently focused. Impairment of ubiquitin-
proteasome system leading to endoplasmic reticulum(ER)
stress, unfolded protein response and consequent aggre-
gation of cytotoxic proteins are involved in the path-
ogenesis of PD (see reviews［46-48］). This hypothesis of proteolytic stress has arisen from the following evi-
dences:that parkin, mutation of which leads to an autosomal recessive form of PD, is a ubiquitin ligase
［49］, thatα-synuclein,mutation of which causes familial PD, is a major component of inclusion Lewy bodies
［50］, and that diﬀerentiated PC12 cells expressing mutant α-synuclein showed a decrease in proteasome activity［51］. ER stress caused by accumulation of unfolded protein leads to up-regulation of parkin protein to prevent unfolded protein response-induced dopaminergic cell death［52］. Dopaminergic neurotoxins 6-OHDA,
MPP?and rotenone induced ER stress and unfolded protein response in catecholaminergic PC12 cells［53］.
The involvement of the ER-Golgi system in dopaminergic cell death in PD is also supported by our recent study showing that rotenone induced disassembly of the Golgi apparatus in dopaminergic cells［54］. In dopaminergic neuroblastoma SH-SY5Y cells and PC12 cells, 6-OHDA increases the levels of free ubiquitin and ubiquitinated
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 proteins, and proteasome inhibition by MG-132 potentiates toxicity of 6-OHDA［55］. Recently, Ho?glin-
ger et al. reported changes in proteasome activities in-
duced by dopaminergic neurotoxins:rotenone and MPP?
reduced proteasome activity via ATP depletion, while 6-OHDA increased the activity in response to oxidative stress in primary cultured mesencephalic dopaminergic neurons［13］. Furthermore, severe inhibition of proteasome activity by the proteasome inhibitor epox-
imicin or MG-132 synergistically exacerbated dopaminer-
gic neurotoxicity of rotenone, MPP?and 6-OHDA, and antioxidant N-acetylcysteine and glucose supplementation protected against the synergistic neurotoxicity［13］.
These reports suggest that proteasome inhibition enhances vulnerability to subtoxic oxidative stress and energy loss by complex I inhibition. Proteasome inhibi-
tion reduces mitochondrial complex I and II activities in SH-SY5Y cells［56］, and up-regulates COX-2 and its ubiquitin conjugates［57］. Thus, proteolytic stress in the ubiquitin-proteasome system is linked not only to oxidative stress but also to mitochondrial dysfunction and the inﬂammatory process. It has been reported that proteasome inhibition leads to formation of ubiquitin/
α-synuclein-positive inclusions in PC12 cells or mesence-
phalic cultured cells［58-60］. Furthermore, unilateral infusion of lactacystin, a proteasome inhibitor, into the substantia nigra or infusion of lactacystin/epoxomicin into the striatum causes selective degeneration of dopaminergic neurons in the substantia nigra with cytoplasmic accumu-
lation of ubiquitin and α-synuclein to form inclusion bodies［60, 61］. The dopaminergic neurotoxic property of overexpressedα-synuclein has been revealed in ani-
Fig.1  Neurotoxicity of quinone formation as a dopaminergic neuron-speciﬁc oxidative stressor which closely links representative hypotheses,
mitochondrial dysfunction, inﬂammation, oxidative stress, and impairment of the ubiquitin-proteasome system in the pathogenesis and progress of sporadic Parkinson’s disease and dopaminergic neurotoxin-induced parkinsonism.
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mals that overexpress wild-type or mutantα-synuclein
［48, 62-66］. It has been suggested that the toxicity of
α-synuclein is due, in part, to the increase in transient formation of pathogenic oligomerized α-synuclein protoﬁbrils at the conversion of ﬁbrils to form Lewy bodies［67］, as will be discussed further below. In contrast to the aggravating eﬀects of severe proteasome inhibition on the neurotoxicity of rotenone, MPP?, and 6-OHDA［13］and the neurotoxic property of wild-type or mutantα-synuclein, Sawada et al.recently reported that moderate proteasome inhibition by lactacystin or MG-132 blocked MPP?-or rotenone-induced cell death of primary cultured dopaminergic neurons, despite the appearance ofα-synuclein-positive inclusions［68］, sug-
gesting that impairment of proteasome plays an important role both inα-synuclein-positive inclusion formation and dopaminergic neuronal death on diﬀerent lines, and that the formation of inclusion bodies actually exerts neuro-
protective, rather than neurotoxic, eﬀects. Thus,
although it remains uncertain whether proteolytic stress due to impairment of the ubiquitin-proteasome system is involved in dopaminergic cell death in PD, such stress may be a common process downstream of the path-
ogenesis of PD.
Supporting Evidence of Mitochondrial Dysfunction, Inﬂammation, Oxidative Stress and Proteolytic Stress in Patients with Sporadic Parkinson’s Disease
 
The activities of mitochondrial complex III in the striatum and of complex I in the substantia nigra are signiﬁcantly reduced in the brain of patients with sporadic PD［69-71］. These ﬁndings support the mitochondrial dysfunction hypothesis mentioned above. It is well known that the inﬂammation is involved in the pathogenesis of PD［22, 72-74］. In fact, in the substantia nigra of patients with PD, activated microglia that express iNOS and COX-1 and-2―which are rate-limiting enzymes that catalyze the formation of prostaglandin precursors from arachidonic acid―were found to be accumulated［75,
76］. Furthermore, inﬂammatory cytokines (IL-1β,
IL-6, TNF-α), an NF-κB transcription factor related to gene induction of cytokines, and some growth factors were increased in the striatum and cerebrospinal ﬂuid of patients with PD［74, 77, 78］. Oxidative stress is thought to play an important role in the pathogenesis and progression of PD. This suggested mechanism is
 
supported by evidence in the brain of patients with sporadic PD showing decreases in the levels of GSH,
GPx and catalase in the basal ganglia, including the striatum and substantia nigra［79-82］, and increases in ferrous ions and iron deposits in the substantia nigra［82,
83］. The most cytotoxic ROS hydroxyl radicals might be generated from hydrogen peroxide through metal-
catalyzed Fenton reaction to cause degenerative reactions including lipid or protein peroxidation and DNA fragmen-
tation［84］. Microglia showing up-regulated iNOS and COX expression and protein nitration were found in the substantia nigra of parkinsonian patients［76, 85］,
suggesting that nitric oxide reacts with superoxide to generate peroxynitrite, which promotes protein nitration.
Concerning the ubiquitin-proteasome system, structural and enzymatic defects of 26S/20S proteasome, especially 20S proteasomeα-subunits, have been revealed in the substantia nigra of patients with sporadic PD［86-88］,
and parkin has also been shown to be present in Lewy bodies in the substantia nigra of patients with non-familial PD［89, 90］, suggesting that proteolytic stress is also involved in the pathogenesis of non-familial PD or parkin-
sonism(see reviews［46-48］).
Neurotoxicity of Quinone Formation as Dopaminergic Neuron-speciﬁc Oxidative Stress
 
These representative hypotheses―i.e., that mitochon-
drial dysfunction, inﬂammation, and the resulting oxidative stress and impairment of the ubiquitin-
proteasome system are common processes in the etiology of PD―can explain the mechanism of neurotoxicity induced by MPTP and 6-OHDA and some parts of pathogenesis in sporadic and familial PD, as mentioned above. However, these hypotheses have not yet fully clariﬁed the mechanisms of dopaminergic neuron-speciﬁc cell loss in PD and rotenone-treated parkinsonian animal models. Although rotenone is not up-taken through DA transporters and systemically inhibits mitochondrial com-
plex I, it also causes highly selective nigrostriatal dopaminergic degeneration with ﬁbrillar cytoplasmic inclu-
sions［14］. It has been shown that ROS generation from the mitochondria of damaged neurons and from microglia through the activation of NADPH oxidase［20, 21］
induces the selective degeneration of nigral DA neurons that are abundant in iron and vulnerable to oxidative stress
［19, 91］. However, this explanation does not fully
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clarify the mechanism of dopaminergic neuron-speciﬁc cell loss, since ROS distributes diﬀusely and its toxic eﬀects are not localized. Recently, Sakka et al. reported that depletion of DA attenuated rotenone-induced neurotox-
icity, suggesting that the existence of endogenous DA itself is involved in the selective loss of dopaminergic neurons induced by rotenone exposure［92］.
In contrast to the general oxidative stress induced by ROS/RNS, neurotoxicity of DA quinones or DOPA quinones have recently received attention as dopaminergic neuron-speciﬁc oxidative stress known to play a role in the pathogenesis of PD and neurotoxin-induced parkinsonism
［3］. There are 2 major pathways in the DA-related oxidative stress (Fig. 1). When an excess amount of cytosolic DA exists outside of the synaptic vesicle, i.e.,
after L-DOPA treatment, DA is easily metabolized via monoamine oxidase-B or by auto-oxidation to produce cytotoxic ROS, and then forms neuromelanin［1, 93］.
In the oxidation of DA by monoamine oxidase, hydrogen peroxide and dihydroxyphenylacetic acid (DOPAC)are generated. On the other hand, non-enzymatic and sponta-
neous auto-oxidation of DA and L-DOPA produces superoxide and reactive quinones such as DA quinones or DOPA quinones［30, 31］. These quinones are easily oxidized to the cyclized aminochromes DA-chrome
(aminochrome)and DOPA-chrome, and then are ﬁnally polymerized to form melanin. Furthermore, other path-
ways of DA oxidation have been reported, and in these pathways, DA quinones are also generated in the en-
zymatic oxidation of DA by prostaglandin H synthase
(COX), lipoxygenase, tyrosinase, and xanthine oxidase
［94-97］. Although the auto-oxidation of DA via quinone formation produces general ROS which shows widespread toxicity not only in DA neurons but also in other regions,
highly reactive DA quinone and DOPA quinone them-
selves have been reported to exert predominant cytotox-
icity in DA neurons and surrounding neural cells, since these quinones are generated from free cytosolic DA outside the synaptic vesicle or from L-DOPA［93］.
The quinones generated from DA or L-DOPA exert cytotoxicity by interacting with various bioactive mole-
cules in or beside dopaminergic neurons. The functional proteins which possess cysteine residues are thought to be the targets of DA quinone and DOPA quinone. These quinones conjugate with the sulfhydryl group of the amino acid cysteine, resulting predominantly in the formation of 5-cysteinyl-DA and 5-cysteinyl-DOPA, respectively［31,
98, 99］. Since the sulfhydryl group on cysteine is often
 
found at the active site of functional proteins, covalent modiﬁcation of cysteine residues by DA quinone or DOPA quinone to form 5-cysteinyl-catechols would irreversibly alter or inhibit protein function and conse-
quently cause cytotoxicity. This mechanism of neurotox-
icity by the formation of 5-cysteinyl-catechols on protein is supported by evidence showing the generation of DA quinone and DOPA quinone, and consequent formation of 5-cysteinyl-catechols, 5-cysteinyl-DA, 5-cysteinyl-
DOPA, and 5-cysteinyl-DOPAC, in the cell loss of dopaminergic neuronal cultured cells treated with DA and L-DOPA［100-102］. In particular, it is of interest that tyrosine hydroxylase, the rate-limiting enzyme in cate-
cholamine biosynthesis, is one of the proteins that may be targeted by the DA quinone generated in the brain, since DA quinones covalently modify and inactivate the DA-
synthesizing enzyme to subsequently form redox-cycling quinoprotein［103, 104］(Fig. 1).
The formation of catechol-quinones in vitro and in vivo has been dramatically blocked by treatment with GSH,
cysteine, or ascorbate［100, 101, 103, 105］, since the reduced sulfhydryl group of cysteine in GSH and free cysteine compete with the sulfhydryl group of cysteine on proteins conjugating with DA or DOPA quinones. We recently revealed the neurotoxic properties of DA-and L-DOPA-related compounds in human neuroblastoma SH-SY5Y cells by generating DA- or DOPA-
semiquinone radicals, which were subsequently converted to toxic quinones［106］. DA or L-DOPA possessing 2 hydroxyl groups on the benzene ring showed marked cell toxicity and generation of DA-or DOPA-semiquinone radicals, as detected by in vitro ESR spectrometry. The cell death and the formation of these semiquinone radicals induced by DA or L-DOPA were markedly prevented by the addition of Cu/Zn-SOD or GSH, but not by the addition of catalase［106］. SOD can act as a superoxide:
semiquinone oxidoreductase to prevent quinone formation
［107］. Furthermore, by conjugating with DA quinone,
GSH prevents the binding of DA quinone to the sulfhy-
dryl groups of cysteine on proteins as described above.
Therefore, the protective eﬀects of SOD and GSH against DA-or L-DOPA-induced cytotoxicity may be the result of the quinone-quenching activities of these antiox-
idants(Fig. 1). The involvement of quinone formation in DA-or DOPA-induced cytotoxicity is also supported by our recent study that overexpression of Cu/Zn-SOD protects SH-SY5Y cells against DA-induced cytotoxicity accompanied by an increase in their GSH level［108］. If
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DA-related neuronal death is caused by the generation of general ROS or RNS, the cytotoxicity of DA would be prevented by antioxidants such as ascorbic acid and
α-tocopherol. However, ascorbic acid andα-tocopherol have lesser or no eﬀects against DA-induced cell death in PC12 cells, while the cell death is markedly inhibited by the thiol-containing compounds GSH, N-acetylcyteine,
and dithiothreitol［109］. Furthermore, these thiol re-
agents prevent auto-oxidation of DA and consequent melanin formation. Taken together, these ﬁndings indi-
cate that quinone formation may play an important role in the neuronal damage induced by dopaminergic neuron-
speciﬁc oxidative stress.
One of the target proteins for DA quinone is thought to beα-synuclein, which is a major component of the insoluble ﬁbrils of Lewy bodies in patients with PD［2］.
The soluble state ofα-synuclein is converted to aggregat-
ed ﬁbrils via transient formation of pathogenic protoﬁbrils by its oligomerization［67］. Mutantα-synuclein(A30P),
which is linked to familial autosomal dominant PD,
enhances the rate of protoﬁbril formation but inhibits the conversion of protoﬁbrils to ﬁbrils, thereby increasing the level of toxic protoﬁbrils［110］, which lead to the destruction of synaptic vesicular membranes［111］.
Conway et al.screened 169 compounds that inhibited the conversion of protoﬁbrils to ﬁbrils, and found that all but one of 15 ﬁbril inhibitors were catecholamines related to DA and L-DOPA. Furthermore, DA quinone reacts withα-synuclein to form the DA quinone-α-synuclein adduct, which inhibits ﬁbril formation at oligomerization by stabilizing the protoﬁbrils［2］. Sinceα-synuclein does not contain cysteine residues, the DA quinone-α-
synuclein adduct may be one of the quinoproteins formed by coupling DA quinone to tyrosine residues ofα-
synuclein and/or by nucleophilic attack of quinone to lysine residues forming a Schiﬀbase［103, 112］(Fig.
1).
In addition to neurotoxic DA quinones, cyclized o-semiquinones derived from DA-chromes are involved in the cytotoxicity induced by auto-oxidation of DA［113-
117］. In the pathway of melanin formation, the cyclized aminochrome DA-chrome (aminochrome) is generated from DA quinone via leukoaminochrome, and is convert-
ed to 5,6-dihydroxyindole and then indole-5,6-quinone,
which is consequently polymerized to form melanin. It has been proposed that reduction of DA-chrome catalyzed by NADPH cytochrome P450 reductase produces cyclized o-DA semiquinone (leukoaminochrome o-
semiquinone)radicals which are highly reactive molecules
［116, 118］. This cytotoxic eﬀect of cyclized o-DA semiquinone derived from DA-chrome is supported by a report showing that unilateral injection of cyclized amino-
chrome, DA-chrome into the substantia nigra resulted in apomorphine-induced rotation behavior with a signiﬁcant reduction of nigral DA neurons［119］.
The cytotoxicity of quinone formation is closely linked not only to general oxidative stress but also to mitochon-
drial dysfunction, inﬂammation, and proteasome impair-
ment (Fig. 1). Quinone formation by DA oxidation reduces mitochondrial function and opens the mitochon-
drial permeability transition pores in the brain［120］.
DHBT-1 (7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-
1,4-benzothiazine-3-carboxylic acid), a further oxidation product of 5-cysteinyl-DA, irreversibly inhibits the activ-
ity of mitochondrial complex I［121］. As described above, several NSAIDs protected against dopaminergic cell loss in MPTP-treated parkinsonian models［23, 24,
26］. Furthermore, reduction of nigral DA neurons by MPTP injection was prevented in COX-2 knockout mice or by treatment with a COX-2 inhibitor［122］. One possible dopaminergic neuron-speciﬁc target molecule of NSAIDs is thought to be prostaglandin H synthase,
which is abundant in the brain［96］. This enzyme,which exerts both COX activity and peroxidase activity on the arachidonic acid cascade, catalyzes the production of prostaglandin G2 from arachidonic acid by its COX activity, and then converts prostaglandin G2 to prosta-
glandin H2/E2 by its peroxidase activity. In the presence of DA, oxidative reaction of DA to form DA quinone is coupled with the latter step. In other words, the DA quinone is generated not only in auto-oxidation of DA,
but also by the enzymatic oxidation of DA by prostaglan-
din H synthase in a reaction mediated by hydrogen peroxide［96］. The NSAIDs indomethacin and aspirin inhibit this prostaglandin H synthase-mediated oxidation of DA［123］. These ﬁndings suggest that the induction of COX and resulting formation of DA quinone play an important role in the degeneration of DA neurons by dopaminergic neurotoxins or excess DA. In fact, pros-
taglandin E2, which is generated by prostaglandin H synthase, is increased in the substantia nigra of patients with PD［123］. Furthermore, the 5-cysteinyl-DA/
homovanillic acid concentration ratio has been shown to be signiﬁcantly higher in the cerebrospinal ﬂuid of the patients with PD who received L-DOPA therapy［124］.
In another study, the 5-cysteinyl-catechols were
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signiﬁcantly higher in the substantia nigra of PD patients than in that of controls［125］. Apoptotic and selective dopaminergic cell death with formation of ubiquitin and
α-synuclein-positive inclusion in vitro or in vivo induced by the proteasome inhibitor lactacystin or epoxomicin was suppressed by reducing endogenous DA, and enhanced by treatment with L-DOPA or the monoamine oxidase inhibitor pargyline［60］. In a related work, DA induced proteasome inhibition in PC12 cells, and this inhibition was attenuated by GSH, monoamine oxidase inhibitors,
or a DA uptake inhibitor［126］. These ﬁndings suggest a possible role of proteasome inhibition in the toxicity induced by high levels of DA or its quinone in the cytosol.
Thus, DA quinone-or DOPA quinone-induced cytotox-
icity is thought to be involved not only in the pathogenesis of PD but also in the adverse reactions induced by long-term L-DOPA therapy.
Neuroprotective Approaches against DA Quinone Cytotoxicity
 
As mentioned above, various studies have introduced neuroprotective approaches against DA quinone toxicity.
The DA-or L-DOPA-induced formation of catechol-
quinones such as 5-cysteinyl-DA and 5-cysteinyl-DOPA and consequent dopaminergic cell damage in vitro and in vivo were dramatically prevented by treatment with SOD,
GSH, N-acetylcyteine, or dithiothreitol, but not by treatment with catalase orα-tocopherol［100, 101, 103,
105, 106, 108, 109］. These protective eﬀects of SOD,
GSH, and some thiol reagents against DA-or L-DOPA-
induced cytotoxicity may be due to their quinone-
quenching activities. SOD exerts protective eﬀects by acting as a superoxide:semiquinone oxidoreductase to prevent quinone formation［106-108］. The sulfhydryl group of free cysteine in GSH and thiol reagents compete with the sulfhydryl group of cysteine on functional pro-
teins conjugating with DA or DOPA quinones［3, 96,
106, 109］. These quinone-quenching reagents, espe-
cially N-acetylcyteine, which can cross the blood-brain barrier, may be therapeutically useful against the neuro-
toxicity of quinone formation that causes oxidative stress speciﬁcally in the dopaminergic neurons.
Against the DA-chrome-induced neurotoxicity, 2 enzymes, NAD(P)H:quinone oxidoreductase (NQO:
DT-diaphorase) and GSH transferase (GST) M2-2,
exert neuroprotective eﬀects to prevent the formation of cyclized o-DA semiquinone (Fig. 1). NQO:DT-diap-
horase(so-called quinone reductase), which is present in the dopaminergic neurons in the substantia nigra［127］,
catalyzes the two-electron reduction of quinones, reduces DA-chrome to leukoaminochrome by competing with NADPH cytochrome P450 reductase, and consequently inhibits the formation of o-semiquinone radicals［113,
115, 128］. Treatment with butylated hydroxyanisole,
dimethyl fumarate (DMF), or tert-butylhydroquinone,
which up-regulates the activity of NQO:DT-diaphorase,
protects against cell death related to quinone formation
［129-132］. GST M2-2 also prevents the formation of cyclized o-semiquinone from DA-chrome by catalyzing the conjugation of DA-chrome with GSH to form 4-
glutathionyl-5,6-dihydroxyindoline［133, 134］. In partic-
ular, DMF increases not only the activity of NQO:
DT-diaphorase but also total intracellular GSH and the activities of GST and GSH reductase［130］to reduce the cytotoxicity associated with DA quinone formation.
The neurotoxicity induced by the dopaminergic neuro-
toxins MPTP, MPP?, and 6-OHDA was blocked by treatment with the NSAIDs, aspirin, salicylate and meloxicam, which inhibit COX activity［23-26］. The NSAIDs indomethacin and aspirin inhibited prostaglandin H synthase-mediated oxidation of DA［123］. The ﬁnal product, prostaglandin E2, which is catalyzed by pros-
taglandin H synthase, was increased in the substantia nigra of patients with PD［123］. The NSAIDs can also inhibit the induction of inﬂammatory cytokines and apoptosis-promoting molecules by suppressing of iNOS expression or NF-κB induction. Therefore, NSAIDs could be neuroprotective agents in the treatment of parkinsonian patients, and especially for treating adverse reactions caused by long-term L-DOPA therapy, through their anti-inﬂammatory action and their reduction of catechol quinone-induced cytotoxicity［3, 135］.
Furthermore, the melanin-synthesizing  enzyme tyrosinase, which catalyzes both the hydroxylation of tyrosine to L-DOPA and the subsequent oxidation of L-DOPA or DA to form melanin, might be useful for reducing the neurotoxicity induced by DA quinone［3］
(Fig. 1), since tyrosinase can rapidly oxidize DA or DA quinone to form melanin［136］. We previously reported that inhibition of tyrosinase dramatically reduced the viability of dopaminergic neuronal cells by increasing the intracellular DA contents, and signiﬁcantly enhanced DA-induced cell death［137］. Tyrosinase also oxidizes 5,6-dihydroxyindole derived from DA-or DOPA-chrome to indole-5,6-quinone. Furthermore, the replacement of
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DA synthesis by tyrosinase has been reported in tyrosine hydroxylase-null mice［138］. Neuromelanin exerts antioxidative properties to inhibit lipid peroxidation,
quenches free radicals, and has a strong chelating ability as regards transition metals, preventing metal-induced neurotoxicity［3, 139］. Therefore, enhancing the activ-
ity of tyrosinase in the brain may prevent or ameliorate the DA quinone or DA-chrome-induced slow progression of cell damage by rapid oxidation of excess amounts of cytosolic DA and L-DOPA to form neuroprotective melanin, and by its DA-synthesizing property.
Concluding Remarks
 
In conclusion, it is of interest that the cytotoxicity of quinone formation is closely related not only to general oxidative stress but also to mitochondrial dysfunction and inﬂammation. In other words, quinone formation by auto-oxidation of DA may play an important role as a DA neuron-speciﬁc common degenerative factor that closely links representative hypotheses, mitochondrial dysfunc-
tion, the inﬂammatory process, oxidative stress, and impairment of the ubiquitin-proteasome system in the pathogenesis and progress of PD. Further studies will be required to clarify the role of quinone formation in patients with PD.
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